With key test still looming, Celgene and Acceleron nab FDA okay for beta-thalassemia med
While pricing concerns continue to cloud the future of bluebird bio’s gene therapy fix, the FDA has given its okay for Celgene and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.